FULC — Fulcrum Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1680581 ·
Last close
$3.51
Market Cap
$233.88M
52W High
$8.37
52W Low
$2.83
ADV30
2,548,608
Next earnings
2026-04-27
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -22,186,000 | -18,891,000 | 346,770,000 | 50,261,000 | 13,467,000 |
| Dec 2025 | 0 | — | -22,693,000 | -20,334,000 | 366,284,000 | 197,533,000 | 17,284,000 |
| Sep 2025 | 0 | — | -21,858,000 | -19,595,000 | 214,858,000 | 47,078,000 | 16,492,000 |
| Jun 2025 | 0 | — | -19,815,000 | -17,296,000 | 228,838,000 | 42,588,000 | 14,460,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-63,558,000
Investing CF
$-96,714,000
Financing CF
$168,355,000
CapEx
$-488,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.15
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-613,169,000
Inventory
—
Receivables
$1,776,000
ST Investments
$283,055,000
EBIT TTM
$-86,552,000
Pretax Income TTM
$-76,116,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -84,769,000 | -74,880,000 | 366,284,000 | 17,284,000 | — | -60,065,000 |
| Dec 2024 | 80,000,000 | -19,834,000 | -9,725,000 | 260,718,000 | 17,684,000 | — | -2,218,000 |
| Dec 2023 | 2,805,000 | -110,664,000 | -97,335,000 | 257,694,000 | 22,501,000 | — | -90,965,000 |
| Dec 2022 | 6,342,000 | -112,134,000 | -109,871,000 | 226,685,000 | 27,743,000 | — | -97,050,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.66
Max Pain — expiry 2026-07-17
max pain strike: $3.00 · spot: $3.46 · call oi: 724 · put oi: 4,569
Expected Move to 2026-07-17:
±$0.46
(13.15%) —
implied range
$3.01 –
$3.92
· ATM straddle on $3.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACIU | AC Immune SA | $238.15M | $2.34 | — |
| IFRX | InflaRx N.V. | $238.61M | $1.62 | — |
| SLGL | Sol-Gel Technologies Ltd. | $239.57M | $73.82 | — |
| ADAG | Adagene Inc. | $240.50M | $3.64 | — |
| FHTX | Foghorn Therapeutics Inc. | $241.31M | $4.11 | — |
News headlines (Yahoo Finance, 1h cache)
A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring
2026-06-05 15:15 · Yahoo
Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-06-05 13:35 · Yahoo
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End
2026-06-03 15:00 · Yahoo
Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today?
2026-06-03 03:04 · Yahoo
This Biotech Stock Plunges 54%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’
2026-06-02 16:13 · Yahoo
Meta Platforms upgraded, Okta downgraded: Wall Street's top analyst calls
2026-06-02 13:43 · Yahoo
Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug
2026-06-02 12:08 · Yahoo
FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk
2026-06-01 21:50 · Yahoo
Fulcrum Therapeutics Discontinues Sickle Cell Disease Program After US FDA Raises Malignancy Concerns
2026-06-01 20:56 · Yahoo
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
2026-06-01 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.